Acetylon Pharmaceuticals
An integrated global pharmaceutical company engaged primarily in the discovery, development and commercialization of innovative therapies for the treatment of cancer and inflammatory diseases through gene and protein regulation.
Launch date
Market cap
-
Enterprise valuation
AUD90—135m (Dealroom.co estimates Jun 2011.)
Boston Massachusetts (HQ)
| Date | Investors | Amount | Round |
|---|---|---|---|
N/A | Spinout | ||
N/A | Seed | ||
$7.3m | Series A | ||
| N/A | $2.0m | Series A | |
| N/A | $12.4m | Series B | |
| N/A | $14.6m | Series B | |
$15.0m | Growth Equity VC | ||
$100m | Growth Equity VC | ||
N/A | Acquisition | ||
| Total Funding | AUD234m | ||